肛門裂傷：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Anal Fissure – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Anal Fissure development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Anal Fissure
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Anal Fissure
The report assesses the active Anal Fissure pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Anal Fissure
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Anal Fissure
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Anal Fissure
• The report also covers the dormant and discontinued pipeline projects related to the Anal Fissure

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Anal Fissure to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Anal Fissure therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

脱毛症：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Alopecia – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Alopecia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Alopecia
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Alopecia
The report assesses the active Alopecia pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Alopecia
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Alopecia
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Alopecia
• The report also covers the dormant and discontinued pipeline projects related to the Alopecia

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Alopecia to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Alopecia therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

アレルギー性鼻結膜炎：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Allergic Rhino-Conjunctivitis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Allergic Rhino-Conjunctivitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Allergic Rhino-Conjunctivitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Allergic Rhino-Conjunctivitis
The report assesses the active Allergic Rhino-Conjunctivitis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Allergic Rhino-Conjunctivitis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Allergic Rhino-Conjunctivitis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Allergic Rhino-Conjunctivitis
• The report also covers the dormant and discontinued pipeline projects related to the Allergic Rhino-Conjunctivitis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Allergic Rhino-Conjunctivitis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Allergic Rhino-Conjunctivitis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

アレルギー性結膜炎：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Allergic Conjunctivitis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Allergic Conjunctivitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Allergic Conjunctivitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Allergic Conjunctivitis
The report assesses the active Allergic Conjunctivitis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Allergic Conjunctivitis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Allergic Conjunctivitis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Allergic Conjunctivitis
• The report also covers the dormant and discontinued pipeline projects related to the Allergic Conjunctivitis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Allergic Conjunctivitis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Allergic Conjunctivitis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

アルコール依存症：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Alcohol Addiction – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Alcohol Addiction development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Alcohol Addiction
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Alcohol Addiction
The report assesses the active Alcohol Addiction pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Alcohol Addiction
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Alcohol Addiction
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Alcohol Addiction
• The report also covers the dormant and discontinued pipeline projects related to the Alcohol Addiction

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Alcohol Addiction to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Alcohol Addiction therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

加齢：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Ageing – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Ageing development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Ageing
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Ageing
The report assesses the active Ageing pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Ageing
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Ageing
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Ageing
• The report also covers the dormant and discontinued pipeline projects related to the Ageing

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Ageing to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Ageing therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

アフリカ睡眠病：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“African Trypanosomiasis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across African Trypanosomiasis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for African Trypanosomiasis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for African Trypanosomiasis
The report assesses the active African Trypanosomiasis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the African Trypanosomiasis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the African Trypanosomiasis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for African Trypanosomiasis
• The report also covers the dormant and discontinued pipeline projects related to the African Trypanosomiasis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this African Trypanosomiasis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of African Trypanosomiasis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

急性呼吸窮迫症候群：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acute Respiratory Distress Syndrome – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acute Respiratory Distress Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acute Respiratory Distress Syndrome
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acute Respiratory Distress Syndrome
The report assesses the active Acute Respiratory Distress Syndrome pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acute Respiratory Distress Syndrome
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acute Respiratory Distress Syndrome
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Respiratory Distress Syndrome
• The report also covers the dormant and discontinued pipeline projects related to the Acute Respiratory Distress Syndrome

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acute Respiratory Distress Syndrome to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acute Respiratory Distress Syndrome therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

急性腎不全(急性腎傷害)：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acute Renal Failure (ARF) (Acute Kidney Injury) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acute Renal Failure (ARF) (Acute Kidney Injury)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acute Renal Failure (ARF) (Acute Kidney Injury)
The report assesses the active Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acute Renal Failure (ARF) (Acute Kidney Injury)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acute Renal Failure (ARF) (Acute Kidney Injury)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Renal Failure (ARF) (Acute Kidney Injury)
• The report also covers the dormant and discontinued pipeline projects related to the Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acute Renal Failure (ARF) (Acute Kidney Injury) to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

急性肺傷害：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acute Lung Injury – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acute Lung Injury development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acute Lung Injury
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acute Lung Injury
The report assesses the active Acute Lung Injury pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acute Lung Injury
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acute Lung Injury
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Lung Injury
• The report also covers the dormant and discontinued pipeline projects related to the Acute Lung Injury

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acute Lung Injury to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acute Lung Injury therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

急性冠症候群：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acute Coronary Syndrome – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acute Coronary Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acute Coronary Syndrome
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acute Coronary Syndrome
The report assesses the active Acute Coronary Syndrome pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acute Coronary Syndrome
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acute Coronary Syndrome
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acute Coronary Syndrome
• The report also covers the dormant and discontinued pipeline projects related to the Acute Coronary Syndrome

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acute Coronary Syndrome to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acute Coronary Syndrome therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

日光角化症：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Actinic Keratosis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Actinic Keratosis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Actinic Keratosis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Actinic Keratosis
The report assesses the active Actinic Keratosis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Actinic Keratosis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Actinic Keratosis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Actinic Keratosis
• The report also covers the dormant and discontinued pipeline projects related to the Actinic Keratosis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Actinic Keratosis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Actinic Keratosis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

先端巨大症：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acromegaly – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acromegaly development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acromegaly
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acromegaly
The report assesses the active Acromegaly pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acromegaly
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acromegaly
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acromegaly
• The report also covers the dormant and discontinued pipeline projects related to the Acromegaly

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acromegaly to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acromegaly therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

尋常性ざ瘡：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acne Vulgaris – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acne Vulgaris development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acne Vulgaris
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acne Vulgaris
The report assesses the active Acne Vulgaris pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acne Vulgaris
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acne Vulgaris
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acne Vulgaris
• The report also covers the dormant and discontinued pipeline projects related to the Acne Vulgaris

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acne Vulgaris to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acne Vulgaris therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

アシネトバクター感染症：パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Acinetobacter Infections – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Acinetobacter Infections development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Acinetobacter Infections
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Acinetobacter Infections
The report assesses the active Acinetobacter Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Acinetobacter Infections
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acinetobacter Infections
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acinetobacter Infections
• The report also covers the dormant and discontinued pipeline projects related to the Acinetobacter Infections

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acinetobacter Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acinetobacter Infections therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress